Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts. more
Time Frame | RAPP | Sector | S&P500 |
---|---|---|---|
1-Week Return | -9.6% | -3.72% | -0.05% |
1-Month Return | -12.99% | -1.85% | 2.75% |
3-Month Return | -1.22% | -11.4% | 7.4% |
6-Month Return | -26.87% | -4.41% | 10.47% |
1-Year Return | -10.77% | 4.13% | 27.57% |
Dec '22 | Dec '23 | |||||
---|---|---|---|---|---|---|
Total Revenue | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |||
Cost of Revenue | 15.00K | 112.00K | [{"date":"2022-12-31","value":13.39,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |||
Gross Profit | (15.00K) | (112.00K) | [{"date":"2022-12-31","value":-1500000,"profit":false},{"date":"2023-12-31","value":-11200000,"profit":false}] | |||
Gross Margin | - | (Infinity%) | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":null,"profit":false}] | |||
Operating Expenses | 10.35M | 36.07M | [{"date":"2022-12-31","value":28.7,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |||
Operating Income | (10.37M) | (36.18M) | [{"date":"2022-12-31","value":-1036700000,"profit":false},{"date":"2023-12-31","value":-3617900000,"profit":false}] | |||
Total Non-Operating Income/Expense | - | 3.93M | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |||
Pre-Tax Income | (10.65M) | (34.78M) | [{"date":"2022-12-31","value":-1065200000,"profit":false},{"date":"2023-12-31","value":-3477600000,"profit":false}] | |||
Income Taxes | - | 10.00K | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |||
Income After Taxes | - | (34.79M) | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-3478600000,"profit":false}] | |||
Income From Continuous Operations | - | (34.79M) | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-3478600000,"profit":false}] | |||
Income From Discontinued Operations | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |||
Net Income | (10.65M) | (34.79M) | [{"date":"2022-12-31","value":-1065200000,"profit":false},{"date":"2023-12-31","value":-3478600000,"profit":false}] | |||
EPS (Diluted) | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |||
These ratios help you determine the liquidity of the company. Higher is better.
RAPP | |
---|---|
Cash Ratio | 45.17 |
Current Ratio | 45.91 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
RAPP | |
---|---|
ROA (LTM) | 0.00% |
ROE (LTM) | 0.00% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
RAPP | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.02 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.98 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
RAPP | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 2.26 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Rapport Therapeutics, Inc. Common Stock (RAPP) share price today is $18.56
Yes, Indians can buy shares of Rapport Therapeutics, Inc. Common Stock (RAPP) on Vested. To buy Rapport Therapeutics, Inc. Common Stock from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RAPP stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Rapport Therapeutics, Inc. Common Stock (RAPP) via the Vested app. You can start investing in Rapport Therapeutics, Inc. Common Stock (RAPP) with a minimum investment of $1.
You can invest in shares of Rapport Therapeutics, Inc. Common Stock (RAPP) via Vested in three simple steps:
The 52-week high price of Rapport Therapeutics, Inc. Common Stock (RAPP) is $29.74. The 52-week low price of Rapport Therapeutics, Inc. Common Stock (RAPP) is $16.55.
The price-to-earnings (P/E) ratio of Rapport Therapeutics, Inc. Common Stock (RAPP) is
The price-to-book (P/B) ratio of Rapport Therapeutics, Inc. Common Stock (RAPP) is 2.26
The dividend yield of Rapport Therapeutics, Inc. Common Stock (RAPP) is 0.00%
The market capitalization of Rapport Therapeutics, Inc. Common Stock (RAPP) is $762.25M
The stock symbol (or ticker) of Rapport Therapeutics, Inc. Common Stock is RAPP